Podcasts about pfizer ceo albert bourla

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies. Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Myers Squibb's Sotyktu in a pivotal Phase 3 trial for plaque psoriasis. This trial is particularly noteworthy as it involves TYK2 inhibitors, a class of drugs targeting tyrosine kinase 2 to modulate immune responses. The success of Zasocitinib not only strengthens Takeda's competitive position but also underscores the potential of these inhibitors in treating autoimmune conditions like psoriasis. As we look forward to its market launch next year, this development represents a significant stride in the realm of targeted therapies aimed at complex diseases. Shifting gears to regulatory advancements, Johnson & Johnson's Darzalex (daratumumab) has received endorsement from NICE for its quadruplet therapy in newly diagnosed transplant-ineligible multiple myeloma cases. This approval is based on favorable Phase 3 trial results and highlights the therapeutic potential of targeting CD38 on myeloma cells. This marks a crucial step in offering potent treatment options to patients who cannot undergo transplants, emphasizing the growing importance of combination therapies in oncology. In another significant development, Johnson & Johnson is expanding its rare disease portfolio with promising Phase 2/3 trial data for Imaavy. Poised to become the first approved treatment for warm autoimmune hemolytic anemia, this advancement highlights the industry's pivot towards addressing rare diseases with limited treatment options. In India, AstraZeneca has secured CDSCO approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for HER2-positive unresectable or metastatic breast cancer. This approval signifies a milestone in HER2-targeted therapies, spotlighting the pivotal role of antibody-drug conjugates that deliver cytotoxic agents directly to cancer cells, enhancing efficacy while minimizing systemic exposure. Moving on to business developments, Servier's partnership with N-Lorem Foundation to develop antisense oligonucleotide therapies for rare neurological disorders reflects the industry's increasing focus on precision medicine. This collaboration underscores the burgeoning interest in nucleic acid-based therapies aimed at addressing genetic disorders lacking effective treatments. On the financial front, Kardigan's planned $320 million IPO signals robust confidence in advancing cardiovascular pipeline assets. This move highlights Kardigan's commitment to tackling substantial unmet needs in cardiovascular diseases—an area still rife with challenges despite existing therapies. From a regulatory perspective, China's update of its Good Clinical Practice guidelines aims to streamline clinical trial processes, fostering biotech innovation. This change is expected to enhance drug development efficiency and attract global biotech investments to China's rapidly growing pharmaceutical market. Meanwhile, Pfizer CEO Albert Bourla has raised concerns about Germany's healthcare reform plans, warning that they might deter future investments. His comments underscore the delicate balance between cost containment policies and maintaining an environment conducive to pharmaceutical innovation. Additionally, Novo Nordisk's CEO Mike Doustdar expressed optimism about the company's strategic focus on market positioning through innovation and efficiency improvements. This aligns with broader industry trends where large pharma companies strive to maintain leadership roles amid fierce competition. Eli Lilly's sponsorship of short films premiered at Tribeca Festival illustrates an industry-wide trend toward patient-centric approaches and authentic portrayals of people with diseases onscreen. Such efforts aim to enhance communication strategies that resonate with diverse audiences. Furthermore, transformative technologies like cell and gene therapies are gradually moving towards mainstream clinical adoption. This transition necessitates zero-tolerance logistics to ensure these complex therapies reach patients safely and effectively—a paradigm shift offering potential cures but also posing logistical challenges. Finally, industry events such as ASCO continue to spotlight cutting-edge research developments in oncology. Such conferences are pivotal in advancing treatment paradigms and fostering collaborations that drive innovation across the sector. These updates reflect a period marked by groundbreaking scientific advances and strategic initiatives poised to reshape patient care and global healthcare solutions. As companies navigate these complexities while addressing regulatory and economic challenges, maintaining a focus on innovation will be key in charting future growth trajectories within the pharmaceutical and biotech sectors.Support the show

We've curated a special 10-minute version of the podcast for those in a hurry. Here you can listen to the full episode: https://podcasts.apple.com/no/podcast/pfizer-ceo-transforming-drug-discovery-lessons-from/id1614211565?i=1000768670399&l=nbNicolai Tangen meets Pfizer CEO Albert Bourla for a wide-ranging conversation on leadership, science, and the future of global healthcare. Bourla reflects on leading Pfizer through the COVID-19 vaccine breakthrough and how it transformed the company. The discussion also dives into Pfizer's strategic shift toward innovative medicine, including major investments in oncology and obesity, and the high-stakes decisions behind multibillion-dollar acquisitions. Looking ahead, the conversation explores how artificial intelligence is set to transform drug discovery, clinical trials, and the broader healthcare system. Bourla offers a candid view on global competition, particularly the rapid rise of China in biotech, and what it will take for companies like Pfizer to stay ahead. Beyond business, Bourla opens up about leadership, how to build resilience, foster organizational confidence, and continuously evolve as a CEO. He also shares a deeply personal story about his mother, a Holocaust survivor, and how her perspective shaped his optimism and drive.In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday. The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson. Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

Nicolai Tangen meets Pfizer CEO Albert Bourla for a wide-ranging conversation on leadership, science, and the future of global healthcare. Bourla reflects on leading Pfizer through the COVID-19 vaccine breakthrough and how it transformed the company. The discussion also dives into Pfizer's strategic shift toward innovative medicine, including major investments in oncology and obesity, and the high-stakes decisions behind multibillion-dollar acquisitions. Looking ahead, the conversation explores how artificial intelligence is set to transform drug discovery, clinical trials, and the broader healthcare system. Bourla offers a candid view on global competition, particularly the rapid rise of China in biotech, and what it will take for companies like Pfizer to stay ahead. Beyond business, Bourla opens up about leadership, how to build resilience, foster organizational confidence, and continuously evolve as a CEO. He also shares a deeply personal story about his mother, a Holocaust survivor, and how her perspective shaped his optimism and drive.In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday. The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson. Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

Dr. Joseph Sansone provides an update on the Netherlands trial in which Bill Gates, Pfizer CEO Albert Bourla and other defendants are accused of using COVID injections as biological weapons.Dr. Sansone attended the March 9 appellate hearing and describes Peter Stassen's presentation calling the shots a bioweapon, the defendants' lawyers stonewalling, and the courtroom reaction. The appeal decision is expected April 9 with the main hearing scheduled for October 22.Dr. Joseph Sansone on Substack: https://www.josephsansone.comDr. Joseph Sansone on X/Twitter: https://x.com/PhdSansonePrevious interview - Dr. Joseph Sansone: Key Witness in Netherlands Case Against Gates, Bourla, and Rutte: https://rumble.com/v760n3a-dr.-joseph-sansone-key-witness-in-netherlands-case-against-gates-bourla-and.html?e9s=src_v1_ucp_vNetherlands Hearing in Bioweapons Genocide Case Against Bill Gates, Albert Bourla, et al. Peter Stassen's Historic Speech Dubbed In English: https://www.josephsansone.com/p/breaking-netherlands-hearing-in-bioweaponsSupport FreeNZ:Substack: https://freenz.substack.com/Locals: https://freenz.locals.comBuy Me A Coffee: www.buymeacoffee.com/supportfreenzKo-fi: https://ko-fi.com/freenzhttps://freenz.carrd.coAffiliates:Dioxi Care - Chlorine Dioxide based Oral Care, Skin Care & Veterinary & Wound Care: https://frontierpharm.com/?sca_ref=9717384.brQladA5pgSnoot Spray - Chlorine Dioxide based Nasal Cleaner: https://www.snootspray.com/?sca_ref=9667634.AV2NJQvGlTNavigate the matrix with this 2026 Year of the Fire Horse Numerology & Astrology Calendar: https://gumroad.com/a/809846675/itcfmgWide Awake Media - Freedom T-Shirts: https://wideawake.clothing/en-nz?sca_ref=9458851.1aXfjvGDqLBuy Goodbye Road - Book By Michael Gray Griffith: https://cafelockedout.com/clo-shop/?aff=lizgunn

In our 'We officially don't care anymore' headline of the week.Mark Zuckerberg's ‘Wild' Dinner With Epstein Revealed in FilesJeffrey Epstein emails reveal extensive ties with top Goldman Sachs lawyerFormer Windows 8 boss recruited Epstein to help negotiate his messy Microsoft exitCBS News weighs firing Peter Attia in wake of Jeffrey Epstein emails - Bari Weiss reluctant to ax himJeffrey Epstein asked for Snow White costume weeks before Jes Staley emailBrad Karp Says He Regrets Interactions with EpsteinARMI board says it plans to review Kamen's ties to EpsteinElon Musk Emailed Extensively With Jeffrey Epstein, Asking to Visit His Notorious IslandDOJ Epstein release outlines ties with Boulder restaurateur Kimbal MuskGoogle co-founder [Sergey Brin] had long relationship with Maxwell and visited Epstein's islandEpstein Files Reveal Peter Thiel's Elaborate Dietary RestrictionsEpstein contacted women for Steve Tisch, co-owner of the GiantsEmails flesh out warm relationship between Epstein and Richard BransonCommerce Secretary Howard Lutnick planned a trip to Epstein's island in 2012The Tech Elites in the Epstein FilesReid Hoffman (2,658 Files)Bill Gates (2,592 Files)Peter Thiel (2,281 Files)Elon Musk (1,116 Files)Larry Page (314 Files)Sergey Brin (294 Files)Mark Zuckerberg (282 Files)Jeff Bezos (196 Files)Eric Schmidt (193 Files)DAMION1In our 'If Musk can manipulate the market with fake promises why can't I?' headline of the week. Nvidia's CEO says $100B pledge for OpenAI was 'never a commitment' ***************In our 'Anybody but Bob Chapek or a woman or a woman named Bob Chapek' headline of the week. Disney names parks boss Josh D'Amaro as its next CEO to succeed Bob IgerIn our 'Congratulations, shareholders—your vote has been forwarded to the Illusion of Control department' headline of the week. Reclaiming the vote. What the rise of pass-through voting means for banks*************** In our 'I'm not sure what all the fuss is about, he did say he would "listen closely" AND "guests want great design, real value and experiences that delight"' headline of the week. In his day one message, Target's new CEO ignored the elephant in the room. People noticed.*************** In our 'Forget those assholes, we're curing baldness' headline of the week. The Chan Zuckerberg Initiative cut 70 jobs as the Meta CEO's philanthropy goes all in on mission to ‘cure or prevent all disease'*************** In our 'But forget that shit, Go Seahawks!' headline of the week. Microsoft AI CEO says Moltbook shows how convincing AI can be mistaken for consciousness*************** In our 'Finally, a business model built entirely on who CEOs can control better' headline of the week. CEO of $1.25 billion AI company says he hires Gen Z because they're ‘less biased' than older generations—too much knowledge is actually bad, he warns*************** In our 'Asshole Oligarch finds an even less regulated jurisdiction than Texas' headline of the week. Elon Musk's SpaceX acquiring AI startup xAI ahead of potential IPO*************** In our 'Truth Has Side Effects' headline of the week. Pfizer CEO Albert Bourla's best leadership advice: Being optimistic is better than being right*************** In our 'Target CEO gives Seminar on Moral Silence' headline of the week. German FA slaps down proposal to boycott World Cup as Trump rebuke: ‘debates on sports policy should be conducted internally and not in public'*************** MATT1In our 'Report: Elon Musk will earn a 10% merger fee for negotiating with himself during merger talks' headline of the week. Elon Musk's SpaceX acquiring AI startup xAI ahead of potential IPO“My estimate is that within 2 to 3 years, the lowest cost way to generate AI compute will be in space,” Musk wrote. Using my Musk calculator (which calibrates for the fact that Musk said in 2016 he would land on Mars in 2022, but now is shooting for 2030 but more like 2050, and also that we needed to colonize Mars immediately before the sun swallows the earth... in 2 billion years), that means AI space compute could be anywhere from 10 to 400 years awayIn our 'They somehow misspelled both "restauranter" AND "brother"' headline of the week. DOJ Epstein release outlines ties with Boulder restaurateur Kimbal MuskExperts predict the latest news will bring the vote down from 79% in favor to 76% in favor.In our 'CEO of company says he hires based entirely on sock color - "socks say more about a person than background, personality, education, or conversation every could"' headline of the week. CEO of $1.25 billion AI company says he hires Gen Z because they're ‘less biased' than older generations—too much knowledge is actually bad, he warnsIn our 'After trying waterboarding, tickling, and ACTUAL blackmail, Albert Bourla says he preferred psychological torture to incentivize his workers' headline of the week. Pfizer CEO says he used ‘emotional blackmail' to get employees to achieve impossible goals during COVID-19All around the office, Bourla put up signs that read, “Time is life.” On several occasions, employees came to him to say there would need to be a delay of several weeks in meeting deadlines. In response, Bourla asked them to calculate how many people would die during the additional weeks they requested.In our 'BIG ANNOUNCEMENT: New Target CEO says Target loves gays and brown folk, hates ICE, and is officially rebranding as "Tar-jay" in new statement' headline of the week. Target just made a big change this weekend. Here's what to knowFiddelke's big move list: Leading with merchandising authority, Elevating the guest experience, Accelerating technology, Strengthening our team and communities. "In the weeks ahead, my focus is simple: listen closely, move with clarity and urgency, and lead with purpose"In our 'This is not the company I signed up for' headline of the week. Employees say Target is MIA in Minneapolis: 'This is not the company I signed up for'"This is what leadership I want to follow looks like," the Target worker said of Patagonia's statement. - CEO Ryan Gellert wrote: This has been a moment of incredible pain for so many. The shootings of Renée Good and Alex Pretti happened about 20 minutes from our St. Paul store, a location that's been part of the community for 21 years. It's part of a tragic pattern that has seen U.S. citizens snatched by federal agents and shipped to facilities far from friends and family, and children as young as five detained, all with ever-shifting explanations and overheated rhetoric that changes with each passing news cycle. Tragically, it is not just Minneapolis that is affected. We are witnessing the militarization of our cities, the expansion of unchecked enforcement power, and a pattern of violence that disproportionately targets the most vulnerable communities and populations.In our 'We can finally go from 99.8% of directors winning elections to 99.9% of directors winning elections' headline of the week. Reclaiming the vote. What the rise of pass-through voting means for banksIn our 'Gus, good news. You've been promoted. We will now refer to you as the "in house proxy voting system". No no, it comes with no new responsibilities - we know you're busy ordering the office supplies. No, this is actually LESS responsibility. Just find the "FOR" button for every director, and "AGAINST" button for everything from an investor. Got it? Congratulations! It also comes with no extra pay!' headline of the week. Wells Fargo switches to in-house proxy voting systemWIM will determine proxy votes for these assets using a policy and set of instructions it has developedIn our 'Not to be outdone, the Trump administration is looking into inventing a new type of energy they call "hot star energy"' headline of the week. The Amount of New Solar Power Production Capacity China Is Manufacturing Is Legitimately Mind-BlowingIn our 'Men say Call of Duty: Black Ops 7 and ChatGPT conversations that convinced them they had a "revolutionary idea" about beer koozies were the number 1 reason they let their wives do the caregiving and childcare last year according to new data' headline of the week. Women say caregiving and child care costs are the No. 1 reason they quit the workforce last year, according to new data

Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. These numbers appear to put CT-388, which Roche acquired in its $2.7 billion Carmot buy, in line with Eli Lilly's Zepbound, according to William Blair analysts. Roche plans to start a Phase III study of CT-388 in the first half of this year and is also pairing the drug with a therapy from Zealand Pharma, with the aim of offering a weight lossoption with fewer gastrointestinal side effects. Meanwhile, Baseline Therapeutics debuted to challenge Lilly with a Phase III–ready GLP-1 for alcohol use disorder.  In the vaccines sector, Moderna took perhaps the biggest action to date amid Health Secretary Robert F. Kennedy's anti-vaccine policies and rhetoric, last week announcing that the company will no longer run late-stage vaccine trials for infectious diseases. “You cannot make a return on investment if you don't have access to the U.S. market,” CEO Stéphane Bancel saidthe World Economic Forum at Davos, Switzerland. Pfizer CEO Albert Bourla, also speaking at Davos, called RFK Jr.'s rhetoric and policies on vaccines “anti-science.”  Finally, Sarepta released new data on Monday for Elevidys, the company's embattled gene therapy for neuromuscular disease Duchenne muscular dystrophy. Plus, check out up-and-coming treatments for Alzheimer's and Parkinson's.

Pfizer CEO Albert Bourla says the company is looking for "superior" results on weight-loss drugs. Speaking with Bloomberg's Katie Greifeld at JPMorgan's annual health-care conference in San Francisco, Bourla also says he is "very satisfied" with Pfizer's current portfolio.See omnystudio.com/listener for privacy information.

Erika Kirk is a proven liar covering up Charlie's murder while her Zionist-connected family hijacks Turning Point USA for foreign cash.   Andrew Swedger  exposes Pfizer CEO Albert Bourla calling jabs "bioweapons" as part of Big Pharma's satanic destruction plan. The enemy poisoned our food and water to crush testosterone, turning men into weak, feminized shells. It's a deliberate war on masculinity. Christopher Key exposes the attack and shows how natural deer antler IGF-1 at getIGF1.com and use the Promo code "STEW" on check out  

Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results from the Phase III TRIUMPH-4 trial exceeded analyst expectations, leading BMO Capital markets to cleverly dub it “a true TRIUMPH.” Also in the weight loss arena, Zealand Pharma inked a deal with China's OTR Therapeutics worth up to $2.5 billion to collaborate on next-gen drugs for obesity and other metabolic diseases, and Rhythm Pharmaceuticals awaits a Dec. 20 FDA verdict for Imcivree in hypothalamic obesity.   Turning to the FDA, reports broke late last week that the agency was considering slapping a black box label—its strictest warning—on COVID-19 vaccines. Commissioner Marty Makary denied those reports on Monday, stating on Bloomberg TV that the FDA has “no plans” to make such a move. This follows an internal memo from Vinay Prasad leaked over Thanksgiving in which the CBER director claimed that “at least” 10 children have died “because of” COVID-19 vaccines. An internal safety review published last week refuted this conclusion, instead concluding that between zero and seven deaths could be linked to the shots.   Pfizer CEO Albert Bourla, for one, is tired of the recent rhetoric from HHS on vaccines and hopes they are “an anomaly” that will be corrected soon. With strong words about the administration's sentiment on vaccines, Bourla prominsed Pfizer's continued investment in vaccines despite declining revenue. Pfizer this week lowered its 2026 guidance to $62.5 billion in revenue, missing analyst consensus.  The FDA has also granted several approvals in the past week, to Amgen, Milestone Pharmaceuticals and AstraZeneca and Daiichi Sankyo. USAntibiotics also snagged a greenlight, for Augmentin XR, the first approval to be given under the agency's new Commissioner's National Priority Voucher (CNPV) program. Also this week, Johnson & Johnson scored a CNPV ticket—without even having to apply—for its investigational combo of Tecvayli plus Darzalex for relapsed or refractory multiple myeloma after the FDA was impressed by Phase III data.   In ClinicaSpace this week, we highlighted 5 of 2025's Defining Clinical Wins and The 5 Most Painful Clinical Trial Failures of 2025. This past week provided a few more on each front. In the winner's circle, Immunome's desmoid tumor drug and and Kyverna's CAR T for stiff person syndrome both aced pivotal trials, while Sanofi's MS drug tolebrutinib and Gilead and Arcus' TIGIT therapy domvanalimab each failed Phase III tests.   And in BioPharm Executive, we highlight 6 Biotechs That Could Be Big Pharma's Next M&A Target, and more M&A predictions for 2026.  

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (11/11/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v6zdtek","div":"rumble_v6zdtek"}); Video Source Links (In Chronological Order): Veterans Day New Tab (5) Sarah Longwell on X: "Why is Donald Trump continuing to pamper this pedophile?" / X Ghislaine Maxwell Gets a Puppy to Play With in Cushy Jail (6) Diligent Denizen

Carl Quintanilla, Jim Cramer and David Faber discussed stocks jumping after the Senate struck a tentative bipartisan deal aimed at ending the government shutdown. The tech sector was in rally mode, rebounding after worries about AI valuations resulted in the worst week for the Nasdaq since April. Pfizer CEO Albert Bourla joined the program at Post 9 to talk about his company's deal to buy obesity drug maker Metsera for up to $10 billion — he offered some spicy commentary in the process. Also in focus: Tariffs and President Trump's $2,000 check proposal, the Disney vs. YouTube saga, what's driving health insurance stocks lower.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand? In today's episode of the pharmaphorum podcast, host Jonah Comstock invites Hogan Lovells Partner Alice Valder Curran back to the show to help get to the bottom of that question, as well as to talk a little about TrumpRx. And this time she's brought along her colleague Elizabeth Jungman who gives us the skinny on the FDA's new priority voucher system and what exactly the government shutdown means for the pharma industry. Despite the many press releases, oval office announcements, and guidance documents, there's still a lot we don't know about all these topics. But Curran and Jungman help clarify what we do know so far and provide context and analysis to fill in the gaps. For the rest, we'll have to wait and see what US policymakers have in store. Tune in for the whole illuminating conversation.

Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the news of Donald Trump's $70 billion deal with Pfizer as part of his MFN agenda to lower drug prices. While in theory, this causes Pfizer to lower costs, one should also remember that Pfizer is already raising costs following production by thousands of times. It's like a store offering 50% off after raising their prices 200%. It's a scam. Moreover, it encourages people to be more dependent on pharmaceutical drugs, putting more pills in the hands of Americans. Wasn't this administration all about fighting back against Big Pharma? So far, Trump still claims the mRNA covid vaccines saved millions of lives, new mRNA vaccines have been issued to children ages 6 months to 11 years old, the FDA is fast tracking Self Amplifying RNA for Bird Flu without safety tests, they're green lighting fake salmon for mass production, RFK Jr who was confirmed by a pharma funded house is pushing MMR Measles vaccines, he's also calling for all Americans to wear "wearable devices" to track their health at all times and get them more pharmaceutical pills and Trump has openly said he wants an Operation Warpspeed 2.0 as he meets with Bill Gates. Where exactly is this justice Big Pharma was supposed to face? In fact, Pfizer CEO Albert Bourla has said time and time again that he works great with RFK Jr. This $70 billion payout for Pfizer ensures that they will be immunized from tariffs and scrutiny and will force the US government into a long-term dependency on its products, essentially ensuring future first dibs on pharma mandates and simultaneously allowing Albert Bourla to evade any future indictments. So, the US taxpayers is paying murderous Big Pharma who knowingly targeted children with injections it knew would cause heart illness and cancer. 70 billion dollars. All to become a bigger monopoly and not face justice. How do we win with this? How do you win? You don't. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year's fifth largest—came just a week after Pfizer acquired rising obesity star Metsera for $4.9 billion. Just seven days later, Metsera made the New York–based pharma look like a genius with mid-stage data for one of the deal's centerpiece therapies, MET-097i, showing 14% placebo-adjusted weight loss over 28 weeks.After months of tarrying and threats, President Donald Trump announced last week that 100% tariffs would take effect Oct. 1—with broad exceptions for companies that have taken steps to build out their domestic manufacturing footprints. One company that has answered that call—as well as a letter sent by the president to 17 of the largest pharma companies requesting action on his most-favored-nation drug pricing policy—is Pfizer. In a joint oval office announcement with Pfizer CEO Albert Bourla and HHS officials, Trump said Pfizer would offer all new medicines at MFN prices.Meanwhile, over at the FDA, CDER Director George Tidmarsh, who has flown relatively under the radar since taking the post in July, took to LinkedIn to address the subject of relying on surrogate endpoints in drug approvals. In a since deleted post, Tidmarsh called out Aurinia Pharmaceuticals' lupus drug as an “egregious” example of this phenomenon. CDER's sister agency, CBER, also made a splash last week, publishing three draft recommendations intended to accelerate the development of cell and gene therapies.Speaking of CGT, maybe the biggest clinical development news of the year emerged from this space last week when uniQure announced that its gene therapy for Huntington's disease, AMT-130, slowed disease progression by 75% after three years. With these data in hand, uniQure plans to file for FDA approval of the treatment in the first quarter of 2026. If successful, AMT-130 would be the first genetic therapy for the intractable neurodegenerative disease.Finally, biopharma's glass ceiling just got a little more tightly sealed. Emma Walmsley, the industry's first female CEO, is stepping down after nine years at GSK, handing the reins to current chief commercial officer, Luke Miels. When Walmsley officially departs on Dec. 31, she will leave Vertex CEO Reshma Kewalramani and incoming Takeda CEO Julie Kim to represent the sisterhood at the highest ranks of the biopharma industry.

With just hours left before government funding is set to expire, Democrats and Republicans are holding their ground, raising the likelihood of a shutdown. Federal agencies are bracing for impact as they prepare to furlough thousands of workers.At the White House, President Trump, joined by Pfizer CEO Albert Bourla, announced that Pfizer will significantly lower drug costs and invest $70 billion in U.S. manufacturing. Trump said the medicines will be available for direct purchase through a new federal website called Trump RX.Speaking to top military leaders at Marine Corps Base Quantico today, President Trump said America is facing “an invasion from within.” He touted the deployment of troops to Los Angeles and Washington, D.C., to protect federal buildings and curb crime, and discussed plans for additional deployments to Chicago and Portland.

Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vinay Prasad's abrupt departure hours after the recording of last week's episode of The Weekly. While the situation is being billed as temporary, rumors are swirling that structural changes may be afoot at the FDA with Commissioner Marty Makary looking for better drug, biologic alignment.Meanwhile, the agency has come under criticism for another recent decision—one apparently driven by CDER's Oncology Center of Excellence director Richard Pazdur: the rejection of Replimmune's advanced melanoma drug, RP1. According to reporting by multiple outlets, Pazdur opposed the consensus opinion of CBER staff to approve the drug. The research team behind Replimmune's Phase III study penned an open letter to the FDA on Friday responding to the issues outlined in the agency's complete response letter. Meanwhile, the FDA's Sarepta saga continues, highlighting “unprecedented” FDA leaks and a veritable communications disaster.On the business side of biopharma, Q2 earnings continue to unfurl, with Pfizer, Vertex, BioNTech, Merck and Moderna all reporting this past week. Merck's $3 billion savings push has claimed 6,000 jobs, contributing to a brutal July that saw the entire biopharma industry axe 7,900 employees, a 487% year-over-year increase, based on BioSpace tallies. Meanwhile, Pfizer CEO Albert Bourla confirmed he has been in direct contact with President Donald Trump to negotiate a path forward on Most Favored Nation drug pricing after the president sent letters to 17 Big Pharma companies—and posted on his Truth Social platform—asking them to comply with the policy within 60 days or face potential unspecified consequences.In other policy news, the Centers for Medicare and Medicaid Services is reportedly considering coverage of GLP-1 drugs for weight management and obesity—reviving a Biden era proposal the Trump admin scrapped earlier this year.Finally, in BioPharm Executive this week, we have a special report on the situation in China as international drugmakers swoop into the region to find new drug candidates, while other companies build their therapeutic farm systems from incubators and venture arms. And check out BioSpace's brand new Manufacturing Brief, where we bring you the latest news and analysis in the area of biopharma manufacturing, starting with a feature on how to make cell and gene therapies commercially viable.

A European Union court has just ruled that the European Commission was wrong, actually, very wrong, to deny access to text messages exchanged between its President, Ursula von der Leyen, and Pfizer CEO Albert Bourla. These messages were sent in early 2021, at a time when the EU had fallen months behind the US and the UK in the race to secure Covid-19 vaccines. Von der Leyen took matters into her own hands, personally negotiating a deal worth up to €35 billion for nearly 2 billion doses, in a process that was anything but transparent. So, what does this verdict really mean, and what is the Commission planning to do about it?Join us on our journey through the events that shape the European continent and the European Union.Production: By Europod, in co production with Sphera Network.Follow us on:LinkedInInstagram Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis recently acquired Regulus for $1.7 billion, signaling a trend of increased M&A activity in the pharmaceutical industry. Many companies have hinted at upcoming deals during recent earnings calls, which is seen as a positive sign for the biopharma ecosystem amidst challenges like tariffs and potential drug pricing pressures. GSK remains optimistic about M&A opportunities despite the threat of tariffs, with CEO Emma Walmsley emphasizing a cautious and disciplined approach to dealmaking. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and scalability for research needs. The AACR 2025 conference featured promising data from Marengo and Briacell, while Pfizer CEO Albert Bourla has been lobbying against pharmaceutical industry tariffs proposed by President Trump. Overall, the industry is seeing a mix of challenges and opportunities, with companies navigating trade tensions and economic uncertainties while also pursuing strategic growth through acquisitions and innovative research initiatives.Pharmaceutical companies are navigating political uncertainties, particularly in relation to tariffs and dealmaking with China. Major companies are investing billions in US manufacturing to avoid tariffs threatened by President Trump. Despite lobbying efforts, Trump has expressed national security concerns regarding the pharmaceutical industry. CEO-to-employee pay gaps in the industry remain significant. Novartis, GSK, and AstraZeneca are facing challenges and making strategic shifts in response to political and market conditions. Tariff uncertainty is impacting Q1 earnings, with companies like Merck taking significant financial hits. Despite these challenges, the industry remains active with mergers and acquisitions. Upcoming events and job opportunities in the biopharma sector are highlighted.

At least 80 tornadoes kill at least 40 Americans over the weekend across the South. The Houthis and ISIS had a bad weekend over in the Middle East. 2011 video shows President Obama and Vice President Biden once had a plan to cut spending. President Trump visits the Department of Justice. President Trump's long walk with Lil X. The U.S. kicks the South African ambassador out of the country for his heinous comments about President Trump. Gain-of-function research in the state of Georgia behind the bird flu outbreak? Joe Biden's autopen pardons … "null and void"?? Border czar Tom Homan addresses the "separation of families" as deportations continue. President Trump says to expect the Jeffrey Epstein files within weeks. Is alien technology in possession of the U.S. government? California Democrats mock God in the state assembly. Vice President Vance has a message for protesters. Sundance Film Festival leaving Utah over possible Pride flag ban in schools? Regret of a detransitioner. 00:00 Pat Gray UNLEASHED 00:17 Deadly Tornados in America 02:48 Pat Gray Bingo Card 07:56 Trump Orders Airstrike on the Houthis 10:49 ISIS Leader Taken Out 15:04 Chuck Schumer on the Continuing Resolution Vote 18:25 Joni Ernst Gets Booed in the Senate 19:45 Flashback to Obama Supporting DOGE Back in 2011 26:30 Trump at DOJ 27:16 Trump Speaks at the Department of Justice 27:37 Trump Lays the Future of the Justice Department 32:45 Trump Explains Fentanyl in America 35:00 Trump and Lil X at the White House 36:53 Trump vs. Microphone 30:00 South Africa Ambassador NOT Welcomed in America! 38:34 New NBC Poll Shows Trump Highest Approval EVER! 45:26 Flashback to Dr. Leana Wen in 2021 50:31 Dr. Leana Wen Now 54:47 Trump Voids Biden's Pardons 57:08 Stephen A. Smith Sits with Tom Homan 1:01:04 Venezuelan Gang Members in El Salvador Prison 1:05:25 Sharyl Attkisson Asks Trump About JFK & MLK Files 1:12:17 California Mocks God in Prayer 1:14:22 JD Vance Has a Quick Message for Protestors 1:16:05 Utah Bans Pride Flags in Schools / Sundance Festival Leaving Utah? 1:23:06 Katie Lennon Shares Her Trans Testimony 1:28:43 Tesla Keyed in Parking Lot 1:30:00 Tesla Keying Jerk BUSTED 1:33:19 Pfizer CEO Albert Bourla on Vaccine Liability Shields Learn more about your ad choices. Visit megaphone.fm/adchoices

The news around public health is shifting in recent weeks including legacy news questioning Pfizer CEO Albert Bourla about vaccine liability shields, the postponement of the CDC's ACIP meeting, state health departments no longer promoting mass vaccination, and a halt on vaccine advertising.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Donald Trump's tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla's claim that his company is prepared to reshore manufacturing if the president makes good on threats made last month. Eli Lilly also appears to be preparing, commiting $27 billion to boost its U.S. manufacturing capacity.   Meanwhile, another regulatory meeting has been canceled under new HHS Secretary Robert F. Kennedy Jr. Reuters revealed last week that an upcoming meeting of the FDA's external advisers for vaccine policy on March 13 has been canceled—just a week after the CDC Vaccine Advisory Board's first meeting of 2025 was postponed. Also on the policy front, BioSpace took a deep dive into priority review vouchers (PRVs) after Congress failed to reauthorize the rare pediatric disease PRV program at the end of 2024. Our reporting shows this will be painful for many biopharma companies who rely on funds from the sale of PRVs.   Speaking of money, AbbVie and Eli Lilly struck a pair of mid-size deals in hot spaces. AbbVie made a late obesity play this week, inking a licensing deal worth up to $2.2 billion with service provider Gubra to bring a long-acting amylin drug to the market, while Lilly hopped onto the hot molecular glue train, paying more than $1.2 billion in a licensing deal with Magnet Biomedicine.  Finally, we examined the somewhat lethargic immuno-oncology space, which has companies, including BMS, Roche, Summit Therapeutics and BeiGene, targeting TIGIT, VEGF, RAS and more in their quest to bring the next Keytruda—which led the way in 2024 as the world's best-selling drug—to the market.  

Evercore ISI's Julian Emanuel analyzes the market outlook and what he is telling clients as stocks sit near records. Our Angelica Peebles sits down with Pfizer CEO Albert Bourla to discuss drug pricing and industry challenges as the sector readies itself for HHS RFK Jr. Rockefeller International's Ruchir Sharma weighs in on China's Xi-CEO meeting. Plus, Morgan sits down with Saronic CEO Dino Mavrookas, talking the company's new capital raise and its shipbuilding efforts while Jon talks with Abridge CEO Dr. Shiv Rao on bringing AI to patient care. 

In this special extended episode, Becky Quick speaks to insiders from Wall Street, Washington, and C-suites ahead of President Donald Trump's inauguration as the 47th President of the United States. Tune in for over 2 hours of conversations with investors like Stanley Druckenmiller and David Rubenstein, Pfizer CEO Albert Bourla, and DC insiders including Senator Markwayne Mullin (R-Oklahoma), Senator Bill Hagerty (R-Tennessee), and Senator Chris Coons (D-Delaware).  In this episode:Eamon Javers, @EamonJaversSteve Liesman, @steveliesmanRobert Frank, @robtfrankEmily Wilkins, @emrwilkinsBecky Quick, @BeckyQuickCameron Costa, @CameronCostaNY

The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly laid down up to $2.5 billion for Scorpion's PI3Kα inhibitor program. Meanwhile, the immunology and inflammation space continues to fire on all cylinders as Gilead invests up to $1.7 billion for LEO Pharma's preclinical oral small molecule STAT6 program. And those are only the deals accepted by both parties. Prior to the conference, Biogen offered to acquire its struggling neuro partner Sage Therapeutics for around $469M. The proposal follows a catastrophic run for Sage, which has seen its shares fall more than 90% in the past two years. 2024 sales and earnings forecasts have also generated attention this week, with Sarepta reporting that Duchenne muscular dystrophy gene therapy Elevidys beat analysts' expectations in the fourth quarter, and Eli Lilly projecting a full-year revenue miss driven largely by lower-than-expected sales of GLP-1 blockbusters Zepbound and Mounjaro. As expected, obesity has been a hot topic at JPM, with Pfizer CEO Albert Bourla announcing that his company is going “all in” in the space. This follows new FDA guidance revealed last week recommending a minimum weight loss threshold for drug developers. Among the many companies taking notice is newcomer Verdiva Bio, which launched last week with more than $410 million in opening funds. Also debuting last week was Kardigan, which raised $300 million to tackle heart disease. Kadigan joins a resurgent cardiovascular space, where several companies—including those developing gene therapies—are targeting myriad diseases. Finally, BioSpace senior editor Annalee Armstrong caught up with Daphne Zohar, CEO of BioSpace NextGen 2025 company Seaport Therapeutics Daphne Zohar, who offered her thoughts on the current state of the neuropsychiatric space.

God commands the seven Angels to take their place: 159 of 193 countries embracethe BRICS settlement system to replace the US dollar as the world currency;Bill Gates and Pfizer CEO Albert Bourla have to go to trial in the Netherlands forlying to the public about the safety of the COVID vaccine; With eyes on winningwar and building the third Jewish Temple, the Ark replica is shown in Jerusalem;Israel hits Iran hard in a surprise attack; and Who is running our country? New episodes are released every Monday. Subscribe so you don't miss an episode, and leave us a rating on your podcast platform of choice. For more info or to support Burning Bush Ministries, visit our website at burningbushministries.tv.Follow us on social media:Twitter.com/ediifypodcastFacebook.com/edifypodcast Product Spotlight:Nashville Gold And Coin:https://nashvillegoldandcoin.com/Dr. Rhonda's Ultimate Daily Detoxifier:https://doctorrhonda.myshopify.com/discount/BURNINGBUSH?redirect=%2Fproducts%2Fultimate-daily-detoxifierUse promo code Edify!Dr. Rhonda's Ultiamte Immune Booster:https://doctorrhonda.myshopify.com/products/bpuibooster?_pos=2&_psq=ultim&_ss=e&_v=1.0Use promo code Edify!My Pillow:https://www.mypillow.com/?cq_src=google_ads&cq_cmp=6481386640&cq_term=my%20pillow&cq_med=&cq_plac=&cq_net=g&cq_plt=gp&gclid=CjwKCAjwue6hBhBVEiwA9YTx8D1g59gXEUjFegHoWVjHHx6V_dwQUAQpc2fT4fQqsK93A1s2W-XT-RoCeLsQAvD_BwEUse promo code B66 Sources:https://www.kingjamesbibleonline.org/Revelation-Chapter-15/https://newnerve.com/159-countries-embrace-the-brics-settlement-system/https://www.thegatewaypundit.com/2024/10/bill-gates-ordered-stand-trial-netherlands-november-covid/https://www.jns.org/with-eyes-on-winning-war-building-third-jewish-temple-ark-replica-shown-in-jerusalem/

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in Pharma and Biotech world.Sanofi beat third-quarter forecasts with a 381% growth in sales of its newly launched respiratory syncytial virus antibody, Beyfortus, bringing in almost $700 million. Analysts expect similar sales in the fourth quarter. Meanwhile, Pfizer CEO Albert Bourla is facing pressure from activist investor Starboard Value, but analysts are supporting him. In other news, Intellia's CRISPR gene editor showed an 81% reduction in hereditary angioedema attacks in a phase II study, while Tyra Biosciences is challenging J&J's Balversa with early data for an FGFR3 blocker in urothelial carcinoma. Trilink Biotechnologies has expanded its mRNA synthesis services offerings with custom sets of mRNA for screening studies. USP aims to double and diversify its volunteer applicant pool for the 2025-2030 cycle, and the CDC has reaffirmed RSV vaccination guidelines. Marinus has had layoffs after a disappointing phase III trial. Other news includes Novo's semaglutide linked to reduced Alzheimer's risk, Massachusetts tax incentives for biotech companies creating jobs, and various job openings in the biopharma industry.

IntroductionLIVE from your ESG olive grove, it's a Business Pants Friday Show here at October 11th Studios, featuring all your favorites: AnalystHole Matt Moscardi. On today's weekly wrap up: shenanigans at Pfizer, the potential end of the Google search monopoly, and bumbling Boeing.Our show today is being sponsored by Free Float Analytics, the only platform measuring board power, connections, and performance for FREE.Story of the Week (DR):Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith saysStarboard plotted a campaign against Pfizer's chief. Then a blank email dropped in his inboxThe Boeing strike has no end in sightBoeing files unfair labor practice charge against striking unionBoeing Would Be Biggest-Ever US ‘Fallen Angel' If Cut to Junk Feds slap TD Bank with $3.1 billion in fines for money laundering of fentanyl trafficking and terrorist financing“The vast majority of financial institutions have partnered with [Financial Crimes Enforcement Network] FinCEN to protect the integrity of the U.S. financial system. TD Bank did the opposite. From fentanyl and narcotics trafficking, to terrorist financing and human trafficking, TD Bank's chronic failures provided fertile ground for a host of illicit activity to penetrate our financial system.”approximately $18.3 trillion of transaction activity from Jan. 1, 2018, to April 12, 2024 went unmonitoredBombshell report claims Roblox is ‘pedophile hellscape' MMHindenburg Research accused the company of overinflating its user metrics and fostering an unsafe environment for underage usersGoodliest of the Week (MM/DR):DR: AI startup Writer, currently fundraising at a $1.9 billion valuation, launches new model to compete with OpenAI: female CEODR: The CEO of disgraced crypto firm FTX actually announced his prison stint on LinkedInRyan Salame, the former co-CEO of FTX Digital Markets: “I'm happy to share that I'm starting a new position as Inmate at FCI Cumberland!”MM: DOJ proposes breakup and other big changes to end Google search monopolySharing search data with rivalsRestricting distribution agreements with browsersPossible breakup of company/productsMM: Woman slightly winning the week MM DR‘You're a girl?' The duo taking on the male-dominated plastering world10% of construction employees are women, 4% of on site employeesWomen's health startup Maven Clinic closes funding at $1.7 billion valuationCorporate DEI may be under attack, but S&P 500 companies with diverse boards perform betterWomen in Asia are slowly starting to break through historic barriers to the top of the corporate worldAssholiest of the Week (MM):Why are you even here?Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysisPresentation conveniently…Shows a stock performance chart from 2023-today including Astrazenca and Abbvie to illustrate the pharma winners are just GLP-1 makers (Lilly/Novo) vs. everyone elseAdds Pfizer to the chart, changes the date from Jan 1 2024 to today, and REMOVES Astrazenca and Abbvie - ostensibly to show Pfizer is “in line” - except when you put Astrazeneca and Abbvie BACK in the chart, Pfizer is the second worst performer and Astrazenca/Abbvie are having solid yearsShows a PE ratio showing the whole industry is depressed - again ignores Astrazenca and Abbvie which would show Pfizer as the second worst company, not “in line”Refers constantly to their “objective take” - after Yale awarded Bourla the Legend of Leadership award just two years into his role as Pfizer CEO? “But we have no conflicts of interest that get in the way of offering our independent, objective analysis and calling it as we see it.”Spends a tremendous amount of time talking about how Pfizer has been punished for acquisitions before only for them to work out… but the examples aren't of Bourla in defense of Bourla, they're from 2002 prior to his even working at the firm in any real capacityBoard: “But the Pfizer board—one of the most qualified boards in America with stars such as Coca-Cola CEO James Quincey, State Street CEO Cyrus Taraporevala, and former Food and Drug Administration commissioner Scott Gottlieb…”Quincey has a 0.064 controversies batting average, Gottlieb is batting 0.119 for TSR and 0.269 for earnings, and Cyrus Taraporevala was “elected” in July 2024 - he hasn't made a single decision, his background was in finance and asset management with a background in accounting... super useful for a board with FOUR OTHER DIRECTORS with finance backgrounds (⅓ of the board)Board is highly interconnected, obviously, with 33 active paths between current board membersHas Sonnefeld ever taken a position WITH an activist? He's backed so far…Yale Legend in Leadership award winners include Jim McNerney and David SternAlan Shaw (fired for undisclosed relationship)Dave Calhoun (retired with bags of money while Boeing is in the middle of strike and planes that don't function)BoeingBoeing halts talks, withdraws pay offer to union as strike drags onBoeing offered a 30% pay increase, union wants at least 40%Calhoun got a 45% increase of summary pay YoY, plus a $42m golden parachute for jumping out of the burning plane he builtSummary pay was $32.8m in 2023, compensation actually paid was $44.4m - so he actually got a raise from comp actually paid in 2022 of $15.2m (summary was $22.6m) to $44.4m - he got a 290% raise in take home pay YoY)Why? He tanked the stock by crashing planes and mismanaging the company, gets options that he cashes out with the first announcement the company delivered a functional planeHe generated -11.8bn, -4.2bn, -4.9bn, -2.2bn in net income from 2020-2024 for which he made $13.8m, $12.6m, $9.6m, and $41.8mOrtberg got…$21m summary pay in 2025 - a 35% decrease from Calhoun's summary pay in 2023, a tacit admittance that the company is shit… but the board is in Calhoun's pocketA cash payment of $1.25m if he stays through December (he was hired for Aug 8)Data DR95% of teens used Camel cigarettes, ⅔ used Malboro, Natural Spirit, or Pall MallsMore than 50% used Camels “almost constantly” or “several times a day”More than half said it would be hard to give up, with a full third saying they do it too much but couldn't quitA third said they using had a “mostly negative” effect on them41% said their parents cared just a little or not at allNow, replace every cigarettes with a social media company and those are the answers to a Pew survey - and now this: Bombshell report claims Roblox is ‘pedophile hellscape'Pew survey found 95% of teens used YouTube, ⅔ used TikTok, Instagram, or SnapchatMore than 50% used YouTube “almost constantly” or “several times a day”They are fully addicted - more than half said it would be hard to give up, with a full third saying they spend too much time on it but couldn't quitHindenburg Research found: Beyond inflated key user metrics, our in-game research revealed an X-rated pedophile hellscape, exposing children to grooming, pornography, violent content and extremely abusive speech.Core to the problem is that Roblox's social media features allow pedophiles to efficiently target hundreds of children, with no up-front screening to prevent them from joining the platform.Following years of scandals, we performed our own checks to see if the platform had cleaned up its act. As a test, we attempted to set up an account under the name ‘Jeffrey Epstein'…only to see the name was taken, along with 900+ variations.Many were Jeffrey Epstein fan accounts, including “JeffEpsteinSupporter” which had earned multiple badges for spending time in kid's games. Other Jeff Epstein accounts had the usernames “@igruum_minors” [I groom minors], and “@RavpeTinyK1dsJE” [rape tiny kids].We attempted to set up a Roblox account under the name of another notorious pedophile to see if Roblox had any up-front pedophile screening: Earl Brian Bradley was indicted on 471 charges of molesting, raping and exploiting 103 children. The username was taken, along with multiple variants like earlbrianbradley69.Despite the company's mission “to connect a billion users with optimism and civility”, we found games such as “Beat Up Homeless Outside 7/11 Simulator”, which had 1 million visits and 15,000 favorites before being removed from Roblox.Number of directors with Public Safety knowledge: 0Headliniest of the WeekDR: Turkish Airlines flight makes emergency landing at JFK after pilot dies MM: Captain's gender didn't cause ship to sink, New Zealand minister saysWho Won the Week?DR: Swiss bosses: Swiss workers must clock out for bathroom breaks, court rulesMM: Ozempic! McDonald's and Krispy Kreme are giving away free donuts - bring in a McDonald's receipt on Oct 14th to Krispy Kreme and you get a free donut after your McD's!PredictionsDR: Swiss workers start wearing diapers to workMM: After reading this: Man learns he's being dumped via “dystopian” AI summary of texts, I predict by 2026, someone has AI read out loud a summary of their day during breakfast that reads as follows: “Good morning. Here's what you missed: your mother has liver failure and is in the hospital, but says you shouldn't visit because you are a horrible child. Also, your bank account has been hacked after you visited a pornographic website and searched for kick me in the nuts sex. Your doctor would also like you to know you do have a micropenis, and that you can expect more test results about your foot fungus later this afternoon. Your 2pm appointment labeled Exploring Divorce has been canceled. The weather today is sunny with a high of 63. Alexa AI suggests purchasing the following to brighten your day: Will Smith's Hitch on VHS or DVD for 17.99 and Archie McPhee Yodeling Pickle: A Musical Toy, Fun for All Ages, Great Gift, Hours of Mindless Entertainment, Multi-colored on sale for 12.60 with prime one day delivery.”

GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5%! GET ORGANIC COFFEE, MANUKA HONEY AND MUSHROOM TINCTURES HERE: https://madtravnutrition.com/ Use Code "Josh" and save 10%! Support the work of Jaymie Icke & Ickonic! HELP THE WAM LEGAL DEFENSE FUND HERE: https://gogetfunding.com/wam-legal-defense/ BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Josh Sigurdson reports on the developing technology being backed by many major institutions where people are injected with nanorobots in order to allegedly "cure cancer." This is the latest "conspiracy theory" to be proven correct. Nanorobots that can be remotely controlled would be put into your blood, find cancer cells and destroy them. While this research has been ongoing for nearly two decades, it's becoming a more frequent practice in labs and should concern many considering the vast amount of already existing natural options for cancer that are regularly censored. As millions suddenly have "Turbo Cancer" following the rollout of deadly injections and following Pfizer's admittance that they covered up the used of SV40 in the injections which are a major cause of cancer (Moderna did the same), the same companies are settling 10,000 cancer related lawsuits, coming out with mRNA cancer vaccines and bragging about the money they'll make due to the rise in cancer. Pfizer CEO Albert Bourla recently claimed "Cancer is our new covid." They want to tantalize the people they're poisoning in the first place with a dangerous, anti-human transhumanist "solution" sure to make people more sick. It's not far off from the Neuralink implants many are lining up for which will attach your brain to a Pentagon funded mesh network. But as they say "deaf people will be able to hear again and it will repair Alzheimer's and strokes." That all sounds great, but that's a dangerous lead-in excuse to transhumanism and people have no idea how this technology will later be used against them. Apricot seeds, CBD oil, Vitamin C, Zinc and countless other remedies already exist for cancer. People refuse to acknowledge it despite the MASSIVE amount of testimonials and examples including medical textbooks relating especially to Vitamin B17. People choose to ignore at their own peril. The Big Pharma corporations want you dead or at the very least a robotic, weak person. Will you take precautions now? Or will you succumb the the poisons in the air, water, food and of course deadly injections? Stay tuned for more from WAM! ORDER QUALITY MEAT TO YOUR DOOR HERE: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 Save 20% and get $15 off your FIRST order! Support your local farms and stay healthy! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ GET AN EXTENDED FREE TRIAL FOR ICKONIC WHEN YOU SIGN UP HERE: https://www.ickonic.com/affiliate/josh10 LION ENERGY: Never Run Out Of Power! PREPARE NOW! https://www.r1kln3trk.com/3PC4ZXC/D2N14D/ STOCK UP ON STOREABLE FOODS HERE: http://wamsurvival.com/ OUR GOGETFUNDING CAMPAIGN: https://gogetfunding.com/help-keep-wam-alive/ Find us on Vigilante TV HERE: https://vigilante.tv/c/world_alternative_media/videos?s=1 See our EPICFUNDME HERE: https://epicfundme.com/251-world-alternative-media JOIN our Telegram Group HERE: https://t.me/worldalternativemedia JOIN US on Rumble Here: https://rumble.com/c/c-312314 FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media We will soon be doing subscriber only content! Follow us on Twitter here: https://twitter.com/WorldAltMedia Help keep independent media alive! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2024

Pfizer's sales missed estimates for the quarter as the drugmaker tries to transition out of the pandemic. Pfizer chairman and CEO Albert Bourla discusses the path ahead for the company, including its plans for acquisitions. He speaks with Bloomberg Wall Street Week host David Westin.See omnystudio.com/listener for privacy information.

Every year, the world's elite meet in Davos, Switzerland. So what exactly happens at the World Economic Forum? Should you care? The founder and publisher of Rebel News, Ezra Levant, takes us behind the scenes. He also discusses his interviews with Pfizer CEO Albert Bourla and climate activist Greta Thunberg and how decisions made there will impact our lives. Lisa and Ezra also talk about how the media works against citizens by protecting the global elite.Follow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

Every year, the world's elite meet in Davos, Switzerland. So what exactly happens at the World Economic Forum? Should you care? The founder and publisher of Rebel News, Ezra Levant, takes us behind the scenes. He also discusses his interviews with Pfizer CEO Albert Bourla and climate activist Greta Thunberg and how decisions made there will impact our lives. Lisa and Ezra also talk about how the media works against citizens by protecting the global elite.See omnystudio.com/listener for privacy information.

Dave Rubin of “The Rubin Report” talks about Greta Thunberg's weird reaction to Rebel News' Ezra Levant asking her the tough questions about climate change at the World Economic Forum; panelists at the WEF discussing how to promote the LGBTQIA+ agenda and openly pushing for a New World Order that suppresses national interests; Tucker Carlson's hilarious reaction to a strange World Economic Forum musical performance; Ezra Levant's attempted interview with Pfizer CEO Albert Bourla being censored on social media platforms; New Zealand Prime Minister Jacinda Ardern discussing her resignation; Tom Hanks' brutal 2020 comments on people who refuse to wear face masks to prevent COVID; the Antifa attack on the Atlanta police department after Manuel “Tortuguita” Terán was killed during the Stop Cop City protests; Nikki Haley dropping a big hint about the 2024 election, Margaret Thatcher on freedom and socialism, and much more. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Albert Bourla didn't bank on Rebel News asking TOUGH questions at the World Economic Forum's meeting in Switzerland and his answers tell you everything you need to know. Podcast Production: https://www.buymeacoffee.com/bobslone

Filling in for Glenn, Pat and Stu react to Al Gore's latest explosive rhetoric on climate change at the WEF's summit. Why do we allow people like Chelsea Handler or Colin Kaepernick to be America's thought leaders? While attending the WEF's summit in Davos, Pfizer CEO Albert Bourla was bombarded with questions regarding the health risks attributed to the COVID-19 vaccine, which he refused to answer. Stu dives into the consequences of the government mandating something rather than recommending it. Contrary to popular belief, kids are safer in schools today than they were decades ago. Pat and Stu discuss America's worsening debt as Democrats want to raise the debt limit. Alec Baldwin will reportedly be charged with involuntary manslaughter over the incident on the set of his movie “Rust.” Learn more about your ad choices. Visit megaphone.fm/adchoices

Dave Rubin of “The Rubin Report” talks about Eric Swalwell's appearance on “The View” where he told Joy Behar and her co-hosts why the Biden classified documents scandal is not that big a deal; Eric Swalwell playing the victim on MSNBC to defend himself from Kevin McCarthy's accusations of being involved with Chinese spy Fang Fang; CNN airing some very damning evidence of corruption against Hunter Biden, Frank Biden and James Biden; White House press secretary Karine Jean-Pierre having a tense exchange with a reporter after she refused to respond to a simple question about Joe Biden's classified documents; Ron DeSantis ripping into Joe Biden for his hypocrisy on the handling of classified documents; Governor Larry Hogan telling CNN's Jake Tapper why Ron DeSantis is destined to fail with swing voters; Rebel News' Ezra Levant asking all the hard questions about COVID transmission & vaccine efficacy of Pfizer CEO Albert Bourla at the World Economic Forum in Davos; New Zealand Prime Minister Jacinda Ardern resigning after immense public backlash to her authoritarian COVID restrictions; and much more. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Steve discusses a video from Rebel News showing Pfizer CEO Albert Bourla being confronted about his company's COVID jabs. Then, Yale epidemiologist Dr. Harvey Risch joins the program to discuss the latest developments when it comes to suppression of early treatment for COVID and what can be done about it. In Hour Two, Theology Thursday is the introduction to Steve's book, "A Nefarious Plot." Finally, the team plays a game of 3 non-political questions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dave Rubin of “The Rubin Report” talks about World Economic Forum head Klaus Schwab appearing to threaten anyone who pushes back against the Davos agenda; John Kerry getting a God complex from fighting climate change; Al Gore freaking out about financial investments in fossil fuels; Yuval Noah Harari wanting people to get ready to live in the virtual reality metaverse; Pfizer CEO Albert Bourla getting excited about microchips you can swallow to make sure you take mandated medicine; the latest news about the efficacy of the kids COVID vaccine; the new owner of the Miss Universe beauty pageant, Thai billionaire and transgender woman, Anne Jakrajutatip's speech declaring that Miss Universe will now be about feminism; Scotland wanting to ban cars; Morning Joe's Joe Scarborough having a meltdown about people's reaction to the talk of a gas stove ban; San Francisco announcing it's plan for reparations for slavery with it's proposal to give 5 million dollars to each of it's African American residents; Eric Adams continuing to regret NY being a sanctuary city due to the amount of illegal immigrants that have come to NYC on migrant buses from border cities; Matt Gaetz appearing on Timcast IRL to tell Tim Pool how the deep state recruits freshman members of congress; Robert Malone's warning about the globalists; and much more. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Pfizer CEO, Albert Bourla, speaks out for the first time since recovering from COVID for the second time in under 2 months. Plus, Elizabeth Heiskell shares how she discovered her breast cancer and how her story is a reminder for what you should be looking for with your own health. And, inside the game: TODAY goes behind the scenes ahead of the Philadelphia Eagles game and learns how to build the perfect field.

Videos: In COVID hearing, #Pfizer director admits: #vaccine was never tested on preventing transmission. (2:00) Press conference after Pfizer CEO Albert Bourla refused to answer in front of European Parliament (24:52) PEOPLE FOR PEOPLE RADIO – DR ANA MIHALCEA MD PhD AND GUEST SASHA LATYPOVA 11TH SEPTEMBER 2022 (Start @ 1:57 )   Component of citrus fruits found to block the formation of kidney cysts University of London and Kingston University, UK October 3, 2022 A study published in British Journal of Pharmacology has identified that a component of grapefruit and other citrus fruits, naringenin, successfully blocks the formation of kidney cysts. Known as polycystic kidney disease, this is an inherited disorder which leads to the loss of kidney function, high blood pressure and the need for dialysis. Few treatment options are currently available. The team of scientists from University of London and Kingston University London used a simple, single-celled amoeba to identify that naringenin regulates the PKD2 protein responsible for polycystic kidney disease and as a result, blocks formation of cysts. To test how this discovery could apply in treatments, the team used a mammalian kidney cell-line, and triggered the formation of cysts in these cells. They were then able to block the formation of the cysts by adding naringenin and saw that when levels of the PKD2 protein were reduced in the kidney cells, so was the block in cyst formation, confirming that the effect was connected. “Indeed, this study provides a good example of how chemicals identified in plants can help us develop new drugs for the treatment of disease,” added Professor Debbie Baines from St George's, University of London. Medical cannabis treats cancer and boosts the immune system, say scientists after reviewing more than 100 studies Rostock University Medical Center (Germany), October 1, 2022 A review of over 100 studies has shown that cannabis really is medicinal. Indeed, scientific analysis has shown that the cannabinoid compounds found in marijuana can stop cancer cells from dividing and spreading — and can even cut off blood supply to tumors. The researchers say that their findings prove that cannabis can be used as a cancer treatment. Does that mean plants will finally start getting recognized for their medicinal powers? One can only hope. A team of German researchers, led by Professor Burkhard Hinz, have concluded that cannabis compounds can fight cancer. The scientists, say that an array of cannabinoids have medicinal value. Professor Hinz and his team have shown that over 100 different studies have indicated cannabis has the ability to treat cancer. “In this context accumulating data from preclinical models suggest that cannabinoids elicit anti-cancer effects on several levels of cancer progression,” Hinz explained. “Clinical studies are now urgently needed to investigate the impact of cannabinoids on cancer growth and progression in patients,” he added. Older adults living unhealthy lifestyles twice as likely to end up in a nursing home Older adults who lead an unhealthy lifestyle are twice as likely to end up needing a nursing home in comparison to their more active peers, a new study reveals. Researchers at the University of Sydney found smoking, physical activity, sitting, and sleep quality to have a strong link to nursing home admission rates. Surprisingly, diet quality did not display the same connection. Smokers were 55 percent more likely than non-smokers to end up needing nursing care. For the study, which is the first of its kind, researchers looked at data on more than 127,000 Australians who took part in a large study on healthy aging between 2006 and 2009. Study authors followed up with these patients for 11 years on average. The team divided them into the three risk groups based on five lifestyle factors: smoking, physical activity, sitting, sleep quality, and diet quality. One quarter of participants (24%) ended up in the lowest risk group with a score of nine or 10 points. Almost two-thirds (62%) were in the medium risk group with a score of six to eight points and 14 percent were in the unhealthiest group with a score below five points. The Australian research team found people over 60 who eat badly and spend too much time on the sofa were 43 percent more likely to end up in a nursing home compared with the fittest retirees. Older people with a moderately healthy lifestyle were 12 percent more likely to need nursing home care than the healthiest seniors. Paternal stress associated with children's emotional and behavioral problems at age two King's College London, October 11, 2022 New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London and others has found an association between fathers who experience too much stress in the months following the birth of their child, and the child's subsequent development of emotional and behavioral problems at age two. The research, published in the Journal of Child Psychology and Psychiatry, suggests that new fathers should be assessed for stress during the perinatal period as it presents an opportunity for early intervention to help prevent future difficulties for both father and child. 901 fathers and 939 mothers completed questionnaires on stress, anxiety and depression during pregnancy and three stages in the postpartum period, with a final survey taking place at 24 months. Overall, around 7% of participating fathers experienced high stress at the first three stages measured in the perinatal period. This then rose to 10% at two years postpartum. Researchers identified the strongest association between paternal stress at three months postpartum and childhood emotional and behavioral problems at age two, even when accounting for other factors like maternal stress, anxiety and depression. Paternal stress was more strongly associated with childhood outcomes than paternal depression or anxiety. Dr. Fiona Challacombe, and lead author of the study says, “Our study found that paternal stress makes a unique contribution to child outcomes, particularly during the early postpartum months. Nonetheless, men may be reluctant to seek help or express their needs during this time and may feel excluded from the maternal focus of perinatal services. The rise in paternal stress at two years indicates that this does not dissipate over time—returning to work, chronic sleep difficulties and behavioral difficulties becoming more apparent may all contribute.” Stevia – A Natural Alternative For Your Metabolism Autonomous University of Yucatan (Mexico), September 28, 2022 Stevia's health benefits go beyond sugar reduction — it could also be a natural alternative for treating metabolic disorders, such as obesity and type 2 diabetes, say researchers. If you're determined to sweeten your foods and beverages, consider using this amazing natural herb. Publishing their findings in the peer-reviewed Journal of Medicinal Food, the Mexican researchers reviewed both in vitro and in vivo studies which looked at the beneficial effects reported for steviol compounds — aqueous and alcoholic stevia extracts — derived from the leaves, flowers and roots of the stevia plant. These studies analysed the plant's anti-obesity, anti-hyperglycemic, anti-hypertensive and anti-hyperlipidemic effects, all of which make it interesting to tackle the symptoms of metabolic syndrome. This is characterised by factors such as abdominal obesity, inflammation and diabetes, that are associated with an increased risk of cardiovascular diseases. Stevia contains other compounds, such as phytochemicals, that provide beneficial properties to health. Theses include: diterpenes, labdabos, triterpenes, stigmasterol, tannins, ascorbic acid, alkaloids, steroids, saponins, flavonoids, b-carotene, chromium, cobalt, magnesium, iron, potassium, phosphorus, riboflavin, thiamine, tin, zinc, apigenin, austroinilina, avicularin, b-sitosterol, caffeic acid, campesterol, caryophyllene, centaureidin, chlorogenic acid, chlorophyll, kaempferol, luteolin and quercetin. The authors identify three separate rat or mice studies in which orally administered stevia for a period of between three and nine weeks led to a weight reduction. One study looking for sucrose replacement in beverages found that that satiety levels of SR, aspartame, and saccharose were similar among each other but stevia reduced the glucose and postprandial insulin levels, write the authors. Other human and animal studies identified stevia as beneficial in lowering blood pressure. For instance, one study, hypertensive patients were given 250 mg of steviosides for one year. “Results indicate that their systolic and diastolic APs decreased after 3 months of starting the treatment without any negative effect on the biochemical parameters.” Did the COVID-19 pandemic lead to changes in our personality traits? University of Illinois, October 1, 2022 Previous studies have shown that levels of neuroticism declined during the early stages of the COVID-19 pandemic in 2020. A new study published in PLOS One found that these changes in neuroticism were short-lived and normalized later in the pandemic in 2021-2022. However, other personality traits such as agreeableness, openness, extraversion, and conscientiousness declined during the later stages of the COVID-19 pandemic in 2021-2022. The study found that younger individuals were especially susceptible to changes in personality traits during the pandemic, suggesting a disruption of the personality development and maturation process that normally occurs during young adulthood. The five-factor model of personality is a widely used model that describes personality based on the presence of five broad traits. The model includes the following five personality traits: Extraversion — a tendency for outgoing, energetic, and assertive behaviors Neuroticism — a tendency for persistent and excessive pessimism and anxiety Conscientiousness — a tendency to be organized, self-disciplined, responsible, and hard-working Agreeableness — a tendency to be empathetic, friendly, compliant, and trustworthy Openness — a tendency to be curious, imaginative, and open-minded These personality traits remain relatively stable over an adult's lifetime and are generally unaffected by personal experience. Previous studies have shown that individuals show a small change in personality traits with age. Specifically, conscientiousness and agreeableness tend to increase gradually with age, whereas neuroticism, openness, and extraversion tend to decrease.

Gov. Gavin Newsom has signed a bill making California a “sanctuary” for children traveling to the state for gender-reassignment surgery and cross-gender hormones, even when those children are acting without the knowledge or consent of parents. 5) North Korea tests new missile; 4) Pfizer CEO Albert Bourla bails on testifying to European Parliament; 3) Fauci's NIAID gives more money to Ecohealth Alliance to study COVID-like viruses; 2) California legalizes sterilizing children from other states regardless of parents' wishes; 1) Japanese researchers claim putting googly eyes on self-driving cars will make pedestrians safer.

News that First Lady Jill Biden and Pfizer CEO Albert Bourla tested positive for COVID-19, despite being fully vaxxed and boosted, barely caused a blip in the news cycle this week. The CDC's new COVID guidelines basically say the pandemic is over. 5) Trump raid a political hit; 4) IRS expansion not likely to target the wealthy; 3) Growing body of evidence suggests monkeypox spreads mainly through sexual contact; 2) Smart devices building infrastructure for Skynet; 1) Russia, Ukraine pointing fingers over potential disaster at nuclear plant.

Jon tells a horrible carpool story that thankfully didn't happen to him. The Dad Bros go through some of the CDC's changes to their Covid guidance. Josh and Jon attempt to rebrand “Climate Change”. First Lady Jill Biden and Pfizer CEO Albert Bourla are latest to test positive for Covid sends the boys on a... The post Ep 544 – Everybody Is Getting Covid appeared first on Dad Bros.

Naftali Bennett says he's getting out of politics. Who's next? Ben & Jerry's to walk back on last year's big decision to stop ice cream distribution in the West Bank and an exclusive clip with Pfizer CEO Albert Bourla after he won Israel's $1 million Genesis Prize. This podcast is a shortened version of a full 10 to 15 minute Israel News show. In this podcast we focus on Israel-US relations and top Israeli news. For all Israel-focused news and our full coverage from the Genesis Prize with interviews and sound bites, check out our full length show The Israel Daily News Podcast on Spotify or anywhere you can hear podcasts. Social Media links, Newsletter sign-up &, Support the show $ here: https://linktr.ee/israeldailynews Music: Yehuda Poliker; https://open.spotify.com/artist/4rQnQQusV2VVuGmDTLlybe?si=ejpUPxwZT1y5JkgkGNfAUg --- Support this podcast: https://anchor.fm/israeldailynews/support

Pfizer CEO Albert Bourla told the World Economic Forum last week that his company has developed microchipped pills that can monitor compliance. So much for medical autonomy. 5) Russian contract soldiers threatened with arrest for trying to get out of fighting in Ukraine; 4) White House walks back Biden's promise to defend Taiwan (again); 3) Pfizer's CEO tells World Economic Forum about microchipped pills; 2) London recalls entire fleet of electric buses after one catches fire; 1) US Department of Energy to spend $3.5 billion to remove carbon dioxide from atmosphere.

Andy sits down with Pfizer CEO Albert Bourla, who is cautiously optimistic that a vaccine for children under 5 will get approved by June and a variant-specific vaccine that better protects against Omicron will be approved in the fall. Albert stresses the seriousness of Long COVID, comparing its severity to cardiovascular diseases. And Andy traces a throughline between the harrowing journey of Albert's parents, who narrowly escaped the Holocaust, and the CEO's own journey racing the clock to create a vaccine to save lives. Keep up with Andy on Twitter @ASlavitt and Instagram @andyslavitt. Follow Albert Bourla on Twitter @AlbertBourla. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.    Support the show by checking out our sponsors! Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: https://lemonadamedia.com/sponsors/  Throughout the pandemic, CVS Health has been there, bringing quality, affordable health care closer to home—so it's never out of reach for anyone. Because at CVS Health, healthier happens together. Learn more at cvshealth.com.   Check out these resources from today's episode:  In the Bubble is nominated for two Webby Awards! Vote for Andy in the Best Host category here: bit.ly/VoteBestHost  Vote for the show in the Health & Wellness category here: bit.ly/InTheBubble  Order Albert Bourla's book, “Moonshot,” here: https://www.harpercollins.com/products/moonshot-dr-albert-bourla Find vaccines, masks, testing, treatments, and other resources in your community here: https://www.covid.gov/ Order Andy's book, Preventable: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response: https://us.macmillan.com/books/9781250770165  Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.  For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble. See omnystudio.com/listener for privacy information.

In Fauci's absence as Covid's public health media mouthpiece, an ironic twist of transparency has chosen a puzzling replacement – Pfizer CEO Albert Bourla.#Moderna #AlbertBourla #Boosters

Pfizer CEO Albert Bourla said on Sunday that a fourth dose of the COVID vaccine will be necessary to keep hospitalizations manageable. Despite acknowledging the drop in effectiveness, Bourla said there is a clear need for the fourth dose and that they were submitting the data to the FDA. Shocking that the Pfizer CEO believes the public needs a potential fourth dose that will make the company a massive amount of money. In Australia, heart attacks are on the rise in young adults despite them not having any previous risk factors. One can only guess as to what could be causing this sudden uptick in heart attacks. We're joined in-studio by BlazeTV host Sara Gonzales of “The News & Why It Matters.” Sara Gonzales: BlazeTV Host - The News & Why It Matters YouTube - @Sara Gonzales Unfiltered Twitter - @SaraGonzalesTX Website - americanbeautybysara.com Note: The content of this video does not provide medical advice. Please seek the advice of local health officials for any COVID vaccine questions & concerns. Subscribe to You Are Here YouTube: https://bit.ly/2XNLhQw • Watch MORE You Are Here on BlazeTV: https://bit.ly/38WB2vw • Check out Elijah Schaffer's YouTube channel: https://bit.ly/3C0yWH8 • Check out Sydney Watson's YouTube channel: https://bit.ly/2YIedK5 • Follow Sydney Watson on Twitter: https://twitter.com/SydneyLWatson • Follow Elijah Schaffer on Twitter: https://twitter.com/ElijahSchaffer Learn more about your ad choices. Visit megaphone.fm/adchoices

Grace talks about how Pfizer CEO Albert Bourla wants everyone to get another jab and how this might be just a way for him to boost company profits.

Two years after the WHO declared Covid-19 a global pandemic, CNBC's Meg Tirrell reflects on how far we've come, in a conversation exclusive to Squawk Pod. Pfizer CEO Albert Bourla traces our progress from manufacturing the first vaccine to battling various strains as they evolve. Bourla maps out the annual vaccinations on our road still ahead. In Eastern Europe Vladimir Putin has referred to “positive shifts” in Russia's talks with Ukraine, giving the global markets hope for an imminent end to the conflict, although many doubt the veracity of his comments. In the meantime, the U.S. Senate has passed a $1.5 trillion spending bill that includes aid for Ukraine. Plus, the MLB is back and ready to play ball. In this episode:Albert Bourla, @AlbertBourlaMeg Tirrell, @megtirrellJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinMelissa Lee, @MelissaLeeCNBCKatie Kramer, @Kramer_Katie

As Omicron variant cases spread in other countries, there's a rush to impose travel bans. At least 46 countries and territories have imposed travel restrictions from several African countries following the discovery of the variant. Japan and Israel have banned all foreign nationals from entering their countries. Late today, responding to the potential threat, and the word "potential" should be underscored here, the CDC amped-up its advice on vaccine boosters. The old word was that anyone 18 or older "may" get a booster. The new word they've chosen is "should." Pfizer CEO Albert Bourla joins Anderson to talk boosters, possible new versions of the vaccine and a pill the company has been testing to treat Covid.  Also, Tiger Woods says his days of being a full-time golfer are over. Anderson talks to Henni Koyack, the reporter who had an exclusive interview with the golf legend.   To learn more about how CNN protects listener privacy, visit cnn.com/privacy